Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria.

    Journal Title:  Am J Hematol Primary Author:  Emadi A Author(s):  Emadi A, Br...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. A Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

    ... (PNH) who have an inadequate response to eculizumab . Patients will be treated with RA101495 for 12 weeks. Note: ... by flow cytometry Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus ...

    Clinical Trial last updated 04/20/2017 - 11:14am.

  3. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study

    ... available for PNH, such as supportive care , eculizumab , and hematopoietic stem cell transplantation (HSCT); only the ...

    Research Article last updated 11/02/2016 - 10:41am.

  4. Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

    ... annual meeting in June focused on the effectiveness of eculizumab (Soliris®). Abstract EHA18ABSSUB-5522 Gerard Socie, ... hemoglobinuria (PNH). Clinical trials have shown that eculizumab (Soliris®) reduces rates of hemolysis , or the destruction ...

    Research Review last updated 05/02/2016 - 9:26am.

  5. Local TV covers AAMDSIF Peer Support Networker

    ... decade of being diagnosed.   Fortunately, Soliris ( eculizumab ) is available to treat the condition and according to Joe, ...

    Article last updated 11/28/2016 - 3:21pm.

  6. Fighting PNH While Helping PNH Patients

    ... went back to my specialist and this wasn’t long after eculizumab (Soliris®) had been approved. I got my first infusion in March ...

    Patient Chronicle last updated 11/21/2016 - 12:47pm.

  7. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

    ... Kingdom were the first to treat patients with PNH with eculizumab , and were therefore able to report on long term results. This ... high rate of blood clotting ( thrombosis ) and that eculizumab reduces the chances of this complication by a factor of about 10. ...

    Research Review last updated 05/02/2016 - 9:24am.

  8. Paroxysmal Nocturnal Hemoglobinuria: The Future Of Complement-Based Therapies

    ... in the clinic, the first complement inhibitor eculizumab has changed the paradigm of PNH treatment. However, a ten-year ... likely they parallel the safety and efficacy profile of eculizumab. However, there is a growing interest for agents which target early ...

    Research Article last updated 08/15/2016 - 9:11am.

  9. Genetic Polymorphism of the Complement Receptor-1 (CR1) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    ... factors that influence how patients will respond to eculizumab . As way of background, some patients with PNH who go on Eculizumab have an increase in their hemoglobin up to the normal range ...

    Research Review last updated 05/02/2016 - 9:25am.

  10. Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

    ... haemoglobinuria (PNH) in patients with resistance to eculizumab due to complement C5 polymorphisms ...

    Clinical Trial last updated 08/26/2016 - 11:59am.